Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX. Novavax, Inc.’s share was ...

In the latest close session, Novavax (NVAX) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy ...

Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...